Esperion Inks Daiichi Licensing Deal For Cholesterol Drugs
Michigan-based pharmaceutical company Esperion Therapeutics said Friday that it could reap as much as $300 million under a licensing agreement to give Daiichi Sankyo Europe the exclusive rights to sell a...To view the full article, register now.
Already a subscriber? Click here to view full article